CTCs Evaluated for PD-L1
PD-L1 in CTCs was assessed in 9 out of 12 patients in the D-Olaparib arm (26.5% of all treated patients) and 5 of them were PD-L1 negative (55.6%) before treatment. After D-Olaparib treatment, 8 out of 9 patients were PD-L1 negative (88.9%) and 1 patient became PD-L1 positive. No association was detected between PD-L1 expression in CTCs and PD-L1 levels as measured by IHC (